Survivin in Solid Tumors: Rationale for Development of Inhibitors

摘要: Survivin is a 16.5 kDa protein that functions to inhibit apoptosis, promote proliferation, and enhance invasion. Absent in most adult tissues, survivin selectively upregulated many human tumors, where its overexpression correlates with poor outcome treatment resistance. Consequently, promising target for cancer therapy. Preclinical data demonstrate inhibition reduces cell increases sensitises cells cytotoxic agents radiotherapy. The pharmacological inhibitors LY2181308 YM155 have demonstrated acceptable toxicity evidence of therapeutic efficacy as single early-phase clinical trials. Current efforts seek define the optimum use combination therapies, it hoped preclinical synergy will translate into improved efficacy. Results from these ongoing studies are keenly awaited.